• Friday, 19 July 2019

Lannett Launches Aspirin And Extended-Release Dipyridamole Capsules


Jul 12, 2019 (7 days ago) |
PHILADELPHIA: Lannett Company, Inc. (NYSE: LCI) announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
Total U.S. sales of Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, was approximately $158 million for the 12 months ended April 2019, according to IQVIA, although actual generic market values are expected to be lower.

The launch of Aspirin and Extended-Release Dipyridamole Capsules, an internally developed product, represents a meaningful opportunity, said Tim Crew, chief executive officer of Lannett. We continue to make progress on a number of operational fronts. Since January of this year, we have improved our capital structure with open market purchases of approximately $62 million of our Term loans, which is in addition to the approximately $67 million of required annual loan amortization, added drug development expertise to our board of directors and, including Aspirin and Extended-Release Dipyridamole, launched seven new products.

Like This Article?
Lannett Launches Aspirin And Extended-Release Dipyridamole Capsules

contact Post your comment

category Read other United States News stories

home page Visit Home Page for latest updates